DNSP-11 - 10ml/10mg - Spray

ADVANCED DELIVERY SYSTEM - CELL PENETRATING PEPTIDE TECHNOLOGY

This product utilizes advanced delivery technology incorporating calibrated cell-penetrating peptide (CPP) systems. The formulation is engineered to support efficient and targeted intracellular delivery of active ingredients, contributing to enhanced transport performance and bioavailability.

SPECIFICATIONS

Product Code: DN1010S

Sequence: PPEAPAEDRSL-NH2

Molecular Formula: C50H81N15O18

Molecular Weight: 1180.27 g/mol

CAS: 616204-22-9

Purity: Technical / Research Grade ≥98%

Other details: No TFA Salt

Form: Liquid Solution

Color: Clear / Slightly opalescent

Total Content: 10 mL / 10 mg

Concentration: 1 mg/mL

Approximate Sprays per Bottle: ~82

Approximate Peptide per Spray: ~122 mcg

Vehicle / Carrier System: Proprietary carrier system

Storage Temperature: 4°C (Do not freeze)

Source: Synthetic

Safety classification: Standard handling

DESCRIPTION

Parkinson’s disease (PD) is one of the most frequently studied neurodegenerative disorders and is characterized by the progressive degeneration of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Experimental and clinical observations indicate that a substantial loss of these neurons precedes the appearance of motor symptoms by several years, highlighting a prolonged subclinical phase of neurodegeneration. Current pharmacological strategies primarily focus on modulating dopamine availability or metabolism in order to compensate for nigrostriatal dysfunction; however, these approaches do not address neuronal loss or promote long-term neuronal survival.

For this reason, increasing attention has been directed toward neuroprotective and neurorestorative research strategies, which aim to modify the pathological microenvironment and support the maintenance or recovery of dopaminergic neuronal phenotypes rather than solely compensating for neurotransmitter deficits.

Within this research context, neurotrophic factors such as glial cell line-derived neurotrophic factor (GDNF) and related molecules have demonstrated significant potential in preclinical models and limited clinical investigations for supporting dopaminergic neuron integrity and function. Despite these promising findings, the clinical translation of full-length neurotrophic proteins is constrained by challenges related to central nervous system delivery, molecular stability, and manufacturing complexity.

As a result, smaller neurotrophic-like peptides with improved bioavailability and structural simplicity have become an area of active investigation. One such molecule is an amidated 11-amino-acid peptide derived from the proGDNF domain, commonly referred to in the literature as dopamine neuron stimulating peptide-11 (DNSP-11).

Experimental studies in animal models have reported that a single localized administration of this peptide was associated with sustained alterations in dopamine and dopamine metabolite levels within the substantia nigra over extended observation periods. In toxin-induced models of dopaminergic degeneration, DNSP-11 exposure has been associated with improvements in motor asymmetry measures and with biochemical changes consistent with preserved dopaminergic function.

In vitro investigations further suggest that DNSP-11 supports the survival of primary mesencephalic neurons and promotes neurite outgrowth. In dopaminergic neuronal cell lines, the peptide has been shown to attenuate cell death induced by neurotoxic stimuli, accompanied by reductions in apoptotic markers such as caspase-3 activity and DNA fragmentation.

Collectively, biochemical interaction studies and functional assays indicate that DNSP-11 may engage molecular pathways shared with other compounds under investigation for dopaminergic system support. Taken together, these findings support the classification of DNSP-11 as a neurotrophic-like research peptide, warranting further investigation in experimental models focused on dopaminergic neuron resilience, neuroadaptation, and degeneration-associated stress.

REFERENCES

All information presented above is derived from in vitro experiments, animal studies, and other preclinical research models. These data are intended solely for basic scientific investigation of biological mechanisms and do not imply any therapeutic, diagnostic, preventive, or clinical use in humans or animals.

J.L. Fuqua et al., "Dynamic Changes in Dopamine Neuron Function after DNSP-11 Treatment: Effects in vivo and Increased ERK 1/2 Phosphorylation in vitro" [PubMed]

J.W.H. Sonne, "Effects of Intranasally Administered DNSP-11 on the Central Dopamine System of Normal and Parkinsonian Fischer 344 Rats" [ResearchGate]

Y.A. Sidorova et al., "Small Molecules and Peptides Targeting Glial Cell Line-Derived Neurotrophic Factor Receptors for the Treatment of Neurodegeneration" [MDPI]

L.H. Bradley, "Dopamine Neuron Stimulating Actions of a GDNF Propeptide" [ESMO]

M.S. Parmar et al., "DNSP-11 reduces 6-OHDA-induced caspase 3/7 activation in an SH-SY5Y cell model: Potential Role of ERK signaling pathway?" [The FASEB Journal]

L.H. Bradley, "The neuroprotective actions of dopamine neuron stimulating peptide-11" [Journal of Neurology & Neurophysiology]

M.J. Stenslik et al., "Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson’s disease" [PubMed]

K.A. Kelps et al., "Evaluation of the Physical and In Vitro Protective Activity of Three Synthetic Peptides Derived from the Pro- and Mature GDNF Sequence" [PubMed]

DISCLAIMER

This product is intended for lab research and development use only. These studies are performed outside of the body. This product is not a medicine or drug and has not been approved by the FDA or EMA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

All product information provided on this website is for informational and educational purposes only.